Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2018 16:01 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors

Spring Bank strengthens Board of Directors with the addition of aprominent biopharma R&D veteran HOPKINTON, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc....
February 20, 2018 16:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results

2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic...
February 12, 2018 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21

Conference Call to be Held at 8:30am Eastern Time HOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company...
January 09, 2018 08:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Strengthens Management Team to Enhance Operations

Appoints Kevin Leach, Ph.D., as Vice President, Nonclinical & Translational Research Promotes Garrett Winslow to General Counsel HOPKINTON, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank...
November 15, 2017 16:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial

Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled...
November 07, 2017 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference

HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
October 31, 2017 06:45 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results

Quarter highlighted by data presentations at two conferences and the initiation of research collaborations Confirms top-line results from the second inarigivir (formerly SB 9200) monotherapy dosing...
October 20, 2017 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference

Inarigivir Phase 2 results confirm antiviral activity & novel mechanism of action Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the...
October 06, 2017 08:30 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.

HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
October 02, 2017 08:30 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy

SB 11285 Shows Potent and Highly-Durable Anti-Tumor Activity in Several Tumor Models HOPKINTON, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a...